Add to ORKGHEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PATIENT WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINI
The Btk inhibitor ibrutinib has significantly changed the management of chronic lymphocytic leukemia...
Introduction Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic le...
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
Hemophagocytic Lymphohistiocytosis (HLH) is a rare syndrome characterized by ineffective T-cell and ...
7th International Eurasian Hematology Congress -- OCT 13-16, 2016 -- Istanbul, TURKEYWOS: 0003911806...
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lympho...
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a rela...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is...
Contains fulltext : 201051.pdf (publisher's version ) (Closed access
Secondary hypogammaglobulinemia (SHG) is characterized by a decrease in total serum immunoglobulin (...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome involving uncontrolled inflammation due to wi...
The Btk inhibitor ibrutinib has significantly changed the management of chronic lymphocytic leukemia...
Introduction Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic le...
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...
Hemophagocytic Lymphohistiocytosis in a Patient with Relapsed Chronic Lymphocytic Leukemia Treated w...
Hemophagocytic Lymphohistiocytosis (HLH) is a rare syndrome characterized by ineffective T-cell and ...
7th International Eurasian Hematology Congress -- OCT 13-16, 2016 -- Istanbul, TURKEYWOS: 0003911806...
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lympho...
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a rela...
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristi...
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction...
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is...
Contains fulltext : 201051.pdf (publisher's version ) (Closed access
Secondary hypogammaglobulinemia (SHG) is characterized by a decrease in total serum immunoglobulin (...
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical res...
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome involving uncontrolled inflammation due to wi...
The Btk inhibitor ibrutinib has significantly changed the management of chronic lymphocytic leukemia...
Introduction Autoimmune cytopenia (AIC) is relatively common in patients with chronic lymphocytic le...
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leuke...